TY - JOUR
T1 - Occasional staining for p63 in malignant vascular tumors
T2 - A potential diagnostic pitfall
AU - Kallen, Michael E.
AU - Nunes Rosado, Flavia G.
AU - Gonzalez, Adriana L.
AU - Sanders, Melinda E.
AU - Cates, Justin M.M.
N1 - Funding Information:
Acknowledgments This study was supported by the Division of Anatomic Pathology at Vanderbilt University Medical Center also in part by the National Cancer Institute (Breast Cancer Specialized Program of Research Excellence (SPORE) P50CA98131) and National Institutes of Health (Vanderbilt-Ingram Cancer Center Support Grant P30CA68485). The authors have no conflicts of interest to disclose.
PY - 2012/1
Y1 - 2012/1
N2 - Expression of p63, a putative marker for epithelial or myoepithelial differentiation, has been used to distinguish spindle cell carcinoma from sarcoma. The specificity of p63 for epithelial differentiation has not been thoroughly evaluated however, since p63 expression has been explored in only a handful of mesenchymal tumors. After observing unexpected immunohistochemical staining for p63 in an angiosarcoma of the breast, we evaluated a series of benign and malignant vascular tumors to determine the frequency of such a finding. Nuclear immunoreactivity to p63 was detected, at least focally, in 24% of malignant vascular tumors other than Kaposi sarcoma, which was uniformly negative. Benign vascular tumors were also negative for p63. Although p63 expression in tumors of vascular differentiation is unusual, it may be seen occasionally in some malignant vascular tumors. Thus, p63 is not entirely specific for epithelial differentiation. Since soft tissue angiosarcomas and hemangioendotheliomas sometimes express cytokeratins, the finding of nuclear p63 represents another potential pitfall in the differential diagnosis between poorly-differentiated carcinomas and vascular neoplasms.
AB - Expression of p63, a putative marker for epithelial or myoepithelial differentiation, has been used to distinguish spindle cell carcinoma from sarcoma. The specificity of p63 for epithelial differentiation has not been thoroughly evaluated however, since p63 expression has been explored in only a handful of mesenchymal tumors. After observing unexpected immunohistochemical staining for p63 in an angiosarcoma of the breast, we evaluated a series of benign and malignant vascular tumors to determine the frequency of such a finding. Nuclear immunoreactivity to p63 was detected, at least focally, in 24% of malignant vascular tumors other than Kaposi sarcoma, which was uniformly negative. Benign vascular tumors were also negative for p63. Although p63 expression in tumors of vascular differentiation is unusual, it may be seen occasionally in some malignant vascular tumors. Thus, p63 is not entirely specific for epithelial differentiation. Since soft tissue angiosarcomas and hemangioendotheliomas sometimes express cytokeratins, the finding of nuclear p63 represents another potential pitfall in the differential diagnosis between poorly-differentiated carcinomas and vascular neoplasms.
KW - Angiosarcoma
KW - Hemangioendothelioma
KW - Hemangioma
KW - Kaposi sarcoma
KW - p63
UR - http://www.scopus.com/inward/record.url?scp=84855286368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855286368&partnerID=8YFLogxK
U2 - 10.1007/s12253-011-9426-3
DO - 10.1007/s12253-011-9426-3
M3 - Article
C2 - 21667345
AN - SCOPUS:84855286368
SN - 1219-4956
VL - 18
SP - 97
EP - 100
JO - Pathology and Oncology Research
JF - Pathology and Oncology Research
IS - 1
ER -